FDA Breakthrough Troubles Emerge In Effort To Speed Development

Inspection schedules, diagnostic review and other issues have emerged as some of FDA’s breakthrough therapy designees wend their way closer to the review and approval stages, and FDA says more guidance will be needed.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America